期刊
LEUKEMIA & LYMPHOMA
卷 51, 期 12, 页码 2159-2170出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2010.525725
关键词
Myeloma; MGUS; smoldering myeloma; prognosis; molecular imaging; molecular profiling
资金
- National Cancer Institute of the National Institutes of Health
Multiple myeloma (MM) is a malignant plasma cell dyscrasia localized in the bone marrow. Recent studies have shown that MM is preceded in virtually all cases by a premalignant state called monoclonal gammopathy of undetermined significance (MGUS). This review focuses on non-IgM MGUS and its progression to MM. Although certain clinical markers of MGUS progression have been identified, it currently is not possible to accurately determine individual risk of progression. This review focuses on the various biologic and molecular markers that could be used to determine the risk of MM progression. A better understanding of the pathogenesis will allow us to define the biological high-risk precursor disease and, ultimately, to develop early intervention strategies designed to delay and prevent full-blown MM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据